Receptor Life Sciences
Pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | $9.7m | Series A | |
| Total Funding | 000k | ||
Related Content
Receptor Life Sciences is a biopharmaceutical company focused on developing FDA-regulated oral and inhaled cannabinoid medicines. The company operates in the pharmaceutical industry, specifically targeting the cannabinoid-based therapeutics market. Receptor Life Sciences serves patients requiring cannabinoid treatments, offering solutions characterized by rapid absorption, high bioavailability, and consistent dosing. The business model revolves around the development and commercialization of these cannabinoid medicines, leveraging proprietary drug delivery technologies to enhance drug absorption and efficacy. Revenue is generated through the sale of these specialized medicines, which are designed to improve patient outcomes compared to existing cannabinoid products. The company has secured patents for its unique compositions and technologies, further solidifying its position in the market.
Keywords: biopharmaceutical, cannabinoid, FDA-regulated, oral medicines, inhaled medicines, rapid absorption, high bioavailability, consistent dosing, drug delivery, patents.